SOBI will market ChrondoCelect in EU, Russia, Middle East and other markets for Cartilage Repair
Swedish Orphan Biovitrum AB) (Sobi) announced that the company has acquired the licencing rights to market and distribute ChondroCelect, a cell-based medicinal product for the repair of cartilage defects of the knee, from TiGenix NV.
ChondroCelect was the first cell-based product to be approved in Europe. It is currently available for patients and reimbursed in Belgium, the Netherlands and Spain. Sobi will continue to market and distribute the product where it is currently available and will work to expand the product's availability to patients in a much wider area, including the rest of the European Union, Norway, Russia, Switzerland, Turkey, and the countries in the Middle East and North Africa.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins